Advisory Research’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-2,339
| Closed | -$382K | – | 373 |
|
|
2022
Q1 | $382K | Sell |
2,339
-750
| -24% | -$122K | 0.03% | 280 |
|
|
2021
Q4 | $524K | Sell |
3,089
-213
| -6% | -$36.1K | 0.04% | 253 |
|
|
2021
Q3 | $623K | Buy |
3,302
+650
| +25% | +$123K | 0.04% | 233 |
|
|
2021
Q2 | $450K | Buy |
2,652
+519
| +24% | +$88.1K | 0.03% | 275 |
|
|
2021
Q1 | $301K | Buy |
+2,133
| New | +$301K | 0.02% | 305 |
|
|
2020
Q4 | – | Sell |
-3,164
| Closed | -$461K | – | 316 |
|
|
2020
Q3 | $461K | Buy |
3,164
+1,355
| +75% | +$197K | 0.04% | 242 |
|
|
2020
Q2 | $268K | Sell |
1,809
-632
| -26% | -$93.6K | 0.02% | 291 |
|
|
2020
Q1 | $266K | Buy |
+2,441
| New | +$266K | 0.02% | 253 |
|
|
2018
Q2 | – | Sell |
-2,922
| Closed | -$348K | – | 364 |
|
|
2018
Q1 | $348K | Buy |
+2,922
| New | +$348K | 0.01% | 335 |
|